Avalo Therapeutics
AVTX • NASDAQ
Avalo Therapeutics is a biotechnology company in the healthcare sector trading on NASDAQ, led by CEO Garry A. Neil, with a market cap of $323.8M.
Market Cap$323.8M
Employees19.0
CEOGarry A. Neil
CountryUnited States of America
Healthcare
Biotechnology
Next EarningsMay 11, 2026 · In 4 weeksQ1 2026
Financials
Avalo Therapeutics FAQ
Common questions about Avalo Therapeutics
Avalo Therapeutics is scheduled to report earnings for Q1 2026 on May 11, 2026.
Avalo Therapeutics has approximately 19 employees.